<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>1,600+ royalty-bearing deals | 537 underlying licensing agreements | 10+ years of comparable transactions | Tailored Executive Briefing availableDublin, Aug. 19, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- <a href="https://www.researchandmarkets.com/reports/3261664/royalty-rates-in-pharmaceutical-and?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4tmhb4&amp;utm_campaign=2329501+-+Royalty+Rates+in+Pharmaceutical+and+Biotechnology+Licensing+Deals+2015-2026&amp;utm_exec=jocamspi" rel="nofollow" target="_blank" title="">Royalty Rates in Pharmaceutical and Biotechnology Licensing Deals 2015-2026</a> has been added to ResearchAndMarkets.com's offering. What is a realistic royalty rate for a pharmaceutical or biotechnology licensing deal - and what evidence can you use to support that rate in a negotiation? Royalty Rates in Pharmaceutical and Biotechnology Licensing Deals 2015-2026 provides an evidence-based resource for answering these questions, drawing on more than 1,600 royalty-bearing licensing transactions. Designed for business development, licensing, valuation, legal, strategy and executive teams, the report enables users to benchmark proposed royalty terms against real-world comparable transactions and evaluate royalties in the context of the wider deal economics, rights structure and development profile of the asset. The objective is not simply to identify a royalty percentage; it is to understand whether that royalty is realistic, how it compares with relevant market precedents, and how it fits within the complete economics of the transaction. Comparable Transactions: Find the Deals That Matter Most A royalty rate is only useful as a benchmark if the underlying transaction is genuinely comparable. The report helps users identify licensing deals that more closely match the asset, technology or transaction they are evaluating, rather than relying on broad industry averages or isolated headline royalty figures. Comparable transactions can be assessed according to factors including: <ul type="none"><li style="list-style-type:disc; margin-bottom:8px;">Development stage</li><li style="list-style-type:disc; margin-bottom:8px;">Therapeutic area</li><li style="list-style-type:disc; margin-bottom:8px;">Technology type</li><li style="list-style-type:disc; margin-bottom:8px;">Company</li><li style="list-style-type:disc; margin-bottom:8px;">Deal type</li><li style="list-style-type:disc; margin-bottom:8px;">Territorial scope</li><li style="list-style-type:disc; margin-bottom:8px;">Exclusivity</li><li style="list-style-type:disc; margin-bottom:8px;">Upfront payments</li><li style="list-style-type:disc; margin-bottom:8px;">Milestone structures</li><li style="list-style-type:disc; margin-bottom:8px;">Overall deal economics</li></ul> This enables business development, licensing, valuation and strategy teams to build a more relevant set of transaction precedents and assess whether proposed royalty terms are realistic, defensible and consistent with market practice. For teams preparing for a negotiation, valuation or internal deal review, this comparable-deal evidence provides a stronger basis for supporting assumptions, challenging proposed terms and identifying the range within which similar transactions have actually been agreed. Why Generic AI Is Not a Substitute for This Intelligence Generic AI tools can search and summarise publicly available information. They do not provide access to proprietary, analyst-curated royalty rate dataset or its structured body of comparable licensing transactions. The report combines: <ul type="none"><li style="list-style-type:disc; margin-bottom:8px;">More than 1,600 royalty-bearing pharmaceutical and biotechnology licensing deals</li><li style="list-style-type:disc; margin-bottom:8px;">537 underlying licensing agreements</li><li style="list-style-type:disc; margin-bottom:8px;">Structured analysis by development stage, therapeutic area, technology, company and deal type</li><li style="list-style-type:disc; margin-bottom:8px;">Detailed financial terms including royalties, upfront payments, milestones and total deal value</li><li style="list-style-type:disc; margin-bottom:8px;">Analysis of exclusivity, territorial rights and transaction structure</li><li style="list-style-type:disc; margin-bottom:8px;">Analyst-curated comparable transaction intelligence built specifically for life sciences licensing and business development</li></ul> An AI search may help locate an individual announcement or summarise a known transaction. This report provides the structured evidence base needed to identify genuinely comparable deals, benchmark royalty rates in context and examine the contractual terms behind hundreds of real licensing agreements. The analyst provides the evidence, structure and expert interpretation needed to support a real licensing decision. Reasons to Buy <ul type="none"><li style="list-style-type:disc; margin-bottom:8px;">Benchmark royalty rates against more than 1,600 real pharmaceutical and biotechnology licensing deals to establish a stronger evidence base for valuation and negotiation</li><li style="list-style-type:disc; margin-bottom:8px;">Identify genuinely comparable transactions by development stage, therapeutic area, technology, company and deal structure rather than relying on broad industry averages</li><li style="list-style-type:disc; margin-bottom:8px;">Review 537 underlying licensing agreements to examine how royalty clauses and related commercial terms are structured in real-world transactions</li><li style="list-style-type:disc; margin-bottom:8px;">Assess whether proposed royalty terms are commercially realistic and defensible by comparing royalty rates, ranges, tiered structures and associated payment terms in similar deals</li><li style="list-style-type:disc; margin-bottom:8px;">Understand the complete economics behind the royalty rate, including how royalties interact with upfront payments, milestones, exclusivity and territorial rights</li><li style="list-style-type:disc; margin-bottom:8px;">Strengthen licensing negotiations, valuations and internal deal approvals with objective comparable-transaction evidence</li><li style="list-style-type:disc; margin-bottom:8px;">Qualifying purchasers may receive a complimentary tailored Executive Briefing, applying the report's evidence to their own asset, technology, platform or partnering priorities</li></ul> Key Questions Answered The report can help users answer commercially important questions including: <ul type="none"><li style="list-style-type:disc; margin-bottom:8px;">What royalty rates have been agreed in genuinely comparable pharmaceutical and biotechnology licensing deals?</li><li style="list-style-type:disc; margin-bottom:8px;">What royalty range may be realistic and defensible for an asset at a particular development stage?</li><li style="list-style-type:disc; margin-bottom:8px;">How do royalty rates vary by therapeutic area, technology and stage of development?</li><li style="list-style-type:disc; margin-bottom:8px;">How do royalty rates interact with upfront payments, milestones, exclusivity and territorial rights?</li><li style="list-style-type:disc; margin-bottom:8px;">When are tiered, escalating or variable royalty structures used, and how are they structured?</li><li style="list-style-type:disc; margin-bottom:8px;">Which comparable transactions provide the strongest evidence for a valuation, negotiation position or internal deal approval?</li></ul> What the Report Includes This edition covers more than 1,600 royalty-bearing pharmaceutical and biotechnology licensing transactions from 2015 to 2026. Coverage includes: <ul type="none"><li style="list-style-type:disc; margin-bottom:8px;">More than 1,600 royalty-bearing licensing transactions</li><li style="list-style-type:disc; margin-bottom:8px;">Royalty rate benchmarking by development stage, therapeutic area, technology, company and deal type</li><li style="list-style-type:disc; margin-bottom:8px;">Tiered royalties, escalators and royalty ranges where disclosed</li><li style="list-style-type:disc; margin-bottom:8px;">Supporting financial terms including upfront payments, milestones and total deal value</li><li style="list-style-type:disc; margin-bottom:8px;">Analysis of exclusivity, territorial rights and overall transaction structure</li><li style="list-style-type:disc; margin-bottom:8px;">537 underlying licensing agreements, including royalty clauses and contractual terms</li><li style="list-style-type:disc; margin-bottom:8px;">Royalty rate trends across 2015-2026</li><li style="list-style-type:disc; margin-bottom:8px;">Structured comparable-deal directories for identifying relevant transaction precedents</li></ul> Access 537 Real Licensing Agreements and Royalty Clauses Royalty terms can be difficult to research because headline announcements often provide only limited information on the detailed economics of a transaction. The dataset provides access to 537 underlying licensing agreements, enabling users to move beyond headline deal announcements and examine how royalty and other commercial provisions are actually structured in real transactions. These agreements can provide insight into areas including: <ul type="none"><li style="list-style-type:disc; margin-bottom:8px;">Royalty percentages and ranges</li><li style="list-style-type:disc; margin-bottom:8px;">Tiered royalty structures</li><li style="list-style-type:disc; margin-bottom:8px;">Sales thresholds</li><li style="list-style-type:disc; margin-bottom:8px;">Royalty escalation and reduction mechanisms</li><li style="list-style-type:disc; margin-bottom:8px;">Royalty duration</li><li style="list-style-type:disc; margin-bottom:8px;">Territory</li><li style="list-style-type:disc; margin-bottom:8px;">Exclusivity</li><li style="list-style-type:disc; margin-bottom:8px;">Sublicensing provisions</li><li style="list-style-type:disc; margin-bottom:8px;">Milestone structures</li><li style="list-style-type:disc; margin-bottom:8px;">Other financial and commercial terms</li></ul> For business development, licensing and legal teams, this provides an opportunity to examine actual contract language and transaction mechanics, rather than relying solely on publicly announced headline terms. Built for Real-World Licensing Decisions and Valuation The report is designed to support real licensing decisions - from initial valuation and comparable deal analysis through negotiation and internal transaction approval. <ul type="none"><li style="list-style-type:disc; margin-bottom:8px;">Business development and licensing teams can identify comparable transactions, benchmark proposed terms and prepare evidence for partner negotiations.</li><li style="list-style-type:disc; margin-bottom:8px;">Valuation and finance teams can use real-world transaction evidence to test royalty assumptions in asset valuations, financial models and forecasts.</li><li style="list-style-type:disc; margin-bottom:8px;">Legal and transaction teams can examine how royalty provisions and related commercial terms are structured in actual agreements.</li><li style="list-style-type:disc; margin-bottom:8px;">Executive and investment committees can use comparable transaction evidence to pressure-test assumptions before approving proposed licensing transactions.</li><li style="list-style-type:disc; margin-bottom:8px;">Consultants, advisers and investors can use the intelligence to support valuation, transaction analysis, due diligence and client engagements.</li></ul> Save Significant Research Time Without Sacrificing Evidence Quality Reliable royalty rate information is fragmented across press releases, regulatory filings, financial disclosures, investor materials and licensing agreements. Finding an individual royalty figure may be relatively straightforward. Building a sufficiently large, structured and genuinely comparable group of transactions to support a valuation or negotiation is a very different research task. The analyst has already consolidated and classified royalty-bearing transactions, financial terms and underlying contracts so users can move directly to identifying and assessing the evidence most relevant to their deal. This enables teams to spend less time assembling fragmented transaction information and more time interpreting the evidence, testing assumptions and preparing for the commercial decision itself. Complimentary Tailored Executive Briefing for Qualifying Purchasers Qualifying purchasers may also receive a complimentary Executive Briefing tailored to their specific technology, product, asset, platform, pipeline or partnering priorities. Drawing on the analyst's proprietary deal intelligence, the briefing can identify: <ul type="none"><li style="list-style-type:disc; margin-bottom:8px;">Relevant comparable transactions</li><li style="list-style-type:disc; margin-bottom:8px;">Royalty rate benchmarks</li><li style="list-style-type:disc; margin-bottom:8px;">Comparable deal structures</li><li style="list-style-type:disc; margin-bottom:8px;">Financial benchmarks</li><li style="list-style-type:disc; margin-bottom:8px;">Potential partners and active dealmakers</li><li style="list-style-type:disc; margin-bottom:8px;">Market and transaction trends relevant to the purchaser's objectives</li><li style="list-style-type:disc; margin-bottom:8px;">Practical observations to support valuation, licensing strategy and negotiation planning</li></ul> The published report provides the market evidence; the tailored briefing helps show how that evidence applies to the purchaser's own commercial situation. Qualifying purchasers are typically pharmaceutical, biotechnology or other life sciences companies with an identifiable product, technology, asset, platform or partnering objective that can be meaningfully benchmarked against the analyst's deal intelligence. For more information about this report, visit <a href="https://www.researchandmarkets.com/reports/3261664/royalty-rates-in-pharmaceutical-and?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=4tmhb4&amp;utm_campaign=2329501+-+Royalty+Rates+in+Pharmaceutical+and+Biotechnology+Licensing+Deals+2015-2026&amp;utm_exec=jocamspi" rel="nofollow" target="_blank" title="our website">our website</a>. About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900</pre> <img alt="" src='https://ml.globenewswire.com/media/NDY2Y2RiM2EtNTVjMy00ZmNlLWJjMjUtNmM2ZmFmMzRjYzEzLTEwMjY3MzctMjAyNi0wOC0xOS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Royalty Rates in Pharmaceutical and Biotechnology Licensing Deals 2015-2026 | Benchmark Royalty Rates Against Real-World Pharmaceutical and Biotechnology Licensing Deals

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn